000170244 001__ 170244
000170244 005__ 20240229133710.0
000170244 0247_ $$2doi$$a10.1002/ijc.33762
000170244 0247_ $$2pmid$$apmid:34398972
000170244 0247_ $$2ISSN$$a0020-7136
000170244 0247_ $$2ISSN$$a1097-0215
000170244 0247_ $$2altmetric$$aaltmetric:111906610
000170244 037__ $$aDKFZ-2021-01852
000170244 041__ $$aEnglish
000170244 082__ $$a610
000170244 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$udkfz
000170244 245__ $$aEpidemiology, genetics and treatment of multiple myeloma and precursor diseases.
000170244 260__ $$aBognor Regis$$bWiley-Liss$$c2021
000170244 3367_ $$2DRIVER$$aarticle
000170244 3367_ $$2DataCite$$aOutput Types/Journal article
000170244 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642420070_11679$$xReview Article
000170244 3367_ $$2BibTeX$$aARTICLE
000170244 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170244 3367_ $$00$$2EndNote$$aJournal Article
000170244 500__ $$a2021 Dec 15;149(12):1980-1996
000170244 520__ $$aMultiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140,000 people being diagnosed with MM per year. While 5-year survival following a diagnosis of MM has improved from 28% in 1975 to 56% in 2012 the disease remains essentially incurable. In this review we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that have led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high-risk MM, those with a reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies such as immunotherapies have the potential to influence MM practice in the future. This article is protected by copyright. All rights reserved.
000170244 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000170244 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170244 650_7 $$2Other$$aclinical presentation
000170244 650_7 $$2Other$$aplasma cell disease
000170244 650_7 $$2Other$$arisks factors
000170244 650_7 $$2Other$$asurvival
000170244 650_7 $$2Other$$atreatment
000170244 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000170244 7001_ $$aHoulston, Richard$$b2
000170244 7001_ $$00000-0002-6133-0164$$aSud, Amit$$b3
000170244 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.33762$$gp. ijc.33762$$n12$$p1980-1996$$tInternational journal of cancer$$v149$$x1097-0215$$y2021
000170244 909CO $$ooai:inrepo02.dkfz.de:170244$$pVDB
000170244 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000170244 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000170244 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000170244 9141_ $$y2021
000170244 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-04$$wger
000170244 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-04$$wger
000170244 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2019$$d2021-02-04
000170244 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2019$$d2021-02-04
000170244 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000170244 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000170244 980__ $$ajournal
000170244 980__ $$aVDB
000170244 980__ $$aI:(DE-He78)B062-20160331
000170244 980__ $$aI:(DE-He78)HD01-20160331
000170244 980__ $$aUNRESTRICTED